These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34795852)

  • 1. Heterocyclic Compounds as Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia (AML).
    Sabnis RW
    ACS Med Chem Lett; 2021 Nov; 12(11):1641-1642. PubMed ID: 34795852
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.
    Sabnis RW
    ACS Med Chem Lett; 2023 Aug; 14(8):1043-1044. PubMed ID: 37583831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.
    Sabnis RW
    ACS Med Chem Lett; 2023 Jul; 14(7):891-892. PubMed ID: 37465297
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Cisar JS; Pietsch C; DeRatt LG; Jacoby E; Kazmi F; Keohane C; Legenski K; Matico R; Shaffer P; Simonnet Y; Tanner A; Wang CY; Wang W; Attar R; Edwards JP; Kuduk SD
    J Med Chem; 2022 Aug; 65(16):11241-11256. PubMed ID: 35925768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biaryl Compounds as Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia (AML).
    Sabnis RW
    ACS Med Chem Lett; 2022 Feb; 13(2):158-159. PubMed ID: 35178168
    [No Abstract]   [Full Text] [Related]  

  • 6. Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia (AML).
    Sabnis RW
    ACS Med Chem Lett; 2021 Feb; 12(2):170-171. PubMed ID: 33603957
    [No Abstract]   [Full Text] [Related]  

  • 7. Indazole and Benzoisoxazole Compounds as Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.
    Sabnis RW
    ACS Med Chem Lett; 2022 May; 13(5):763-764. PubMed ID: 35586439
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
    Sykes DB; Kfoury YS; Mercier FE; Wawer MJ; Law JM; Haynes MK; Lewis TA; Schajnovitz A; Jain E; Lee D; Meyer H; Pierce KA; Tolliday NJ; Waller A; Ferrara SJ; Eheim AL; Stoeckigt D; Maxcy KL; Cobert JM; Bachand J; Szekely BA; Mukherjee S; Sklar LA; Kotz JD; Clish CB; Sadreyev RI; Clemons PA; Janzer A; Schreiber SL; Scadden DT
    Cell; 2016 Sep; 167(1):171-186.e15. PubMed ID: 27641501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia.
    Branstrom A; Cao L; Furia B; Trotta C; Santaguida M; Graci JD; Colacino JM; Ray B; Li W; Sheedy J; Mollin A; Yeh S; Kong R; Sheridan R; Baird JD; O'Keefe K; Spiegel R; Goodwin E; Keating S; Weetall M
    Front Oncol; 2022; 12():832816. PubMed ID: 35223511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.
    Zhang L; Zhang J; Wang J; Ren C; Tang P; Ouyang L; Wang Y
    Eur J Med Chem; 2022 Mar; 232():114176. PubMed ID: 35151222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
    Lolli ML; Sainas S; Pippione AC; Giorgis M; Boschi D; Dosio F
    Recent Pat Anticancer Drug Discov; 2018; 13(1):86-105. PubMed ID: 29119937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
    Kadir MFA; Othman S; Nellore K
    Curr Pharm Biotechnol; 2020; 21(15):1654-1665. PubMed ID: 32525770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.
    So J; Lewis AC; Smith LK; Stanley K; Franich R; Yoannidis D; Pijpers L; Dominguez P; Hogg SJ; Vervoort SJ; Brown FC; Johnstone RW; McDonald G; Ulanet DB; Murtie J; Gruber E; Kats LM
    EMBO Mol Med; 2022 Jul; 14(7):e15203. PubMed ID: 35514210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study.
    Galati S; Sainas S; Giorgis M; Boschi D; Lolli ML; Ortore G; Poli G; Tuccinardi T
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia.
    Bernstein ID; Singer JW; Smith FO; Andrews RG; Flowers DA; Petersens J; Steinmann L; Najfeld V; Savage D; Fruchtman S
    Blood; 1992 Apr; 79(7):1811-6. PubMed ID: 1373089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting mitochondrial metabolism in acute myeloid leukemia.
    Rex MR; Williams R; Birsoy K; Ta Llman MS; Stahl M
    Leuk Lymphoma; 2022 Mar; 63(3):530-537. PubMed ID: 34704521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria.
    Kaddu S; Zenahlik P; Beham-Schmid C; Kerl H; Cerroni L
    J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):966-78. PubMed ID: 10365929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies.
    Yokoyama A; Okabe-Kado J; Wakimoto N; Kobayashi H; Sakashita A; Maseki N; Nakamaki T; Hino Ki; Tomoyasu S; Tsuruoka N; Motoyoshi K; Nagata N; Honma Y
    Blood; 1998 Mar; 91(6):1845-51. PubMed ID: 9490665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
    Knecht W; Henseling J; Löffler M
    Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.